Corbus Pharmaceuticals Holding Stock Buy Hold or Sell Recommendation
| CRBP Stock | USD 37.70 1.54 3.92% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Corbus Pharmaceuticals Holding is 'Hold'. Macroaxis provides Corbus Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CRBP positions. The advice algorithm takes into account all of Corbus Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Corbus Pharmaceuticals' buy or sell advice are summarized below:
Real Value 45.65 | Target Price 71 | Hype Value 41.34 | Market Value 37.7 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Corbus Pharmaceuticals Holding given historical horizon and risk tolerance towards Corbus Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Corbus Pharmaceuticals Holding, the advice is generated through an automated system that utilizes algorithms and statistical models.
Corbus |
Execute Corbus Pharmaceuticals Buy or Sell Advice
The Corbus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Corbus Pharmaceuticals Holding. Macroaxis does not own or have any residual interests in Corbus Pharmaceuticals Holding or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Corbus Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Good | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Corbus Pharmaceuticals Trading Alerts and Improvement Suggestions
| Corbus Pharmaceuticals is way too risky over 90 days horizon | |
| Corbus Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Corbus Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (44.6 M) with loss before overhead, payroll, taxes, and interest of (16.14 M). | |
| Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (36.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Corbus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Cannabis Stock Movers For April 22, 2024 |
Corbus Pharmaceuticals current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Corbus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Corbus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Corbus Pharmaceuticals Returns Distribution Density
The distribution of Corbus Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Corbus Pharmaceuticals' future price movements. The chart of the probability distribution of Corbus Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Corbus Pharmaceuticals Holding price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Corbus Pharmaceuticals returns is essential to provide solid investment advice for Corbus Pharmaceuticals.
| Mean Return | 4.89 | Value At Risk | -9.63 | Potential Upside | 16.52 | Standard Deviation | 31.94 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Corbus Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Corbus Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Corbus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Corbus Pharmaceuticals Holding backward and forwards among themselves. Corbus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Corbus Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Group One Trading, Lp | 2023-12-31 | 1.8 K | Tower Research Capital Llc | 2023-12-31 | 1.2 K | Jtc Employer Solutions Trustee Ltd | 2023-12-31 | 1.1 K | Citigroup Inc | 2023-12-31 | 566 | Jpmorgan Chase & Co | 2023-12-31 | 543 | Ubs Group Ag | 2023-12-31 | 321 | Advisor Group Holdings, Inc. | 2023-12-31 | 246 | Carmichael Hill & Associates Inc | 2023-12-31 | 100.0 | Bfsg, Llc | 2023-12-31 | 61.0 | Ikarian Capital, Llc | 2023-12-31 | 195.9 K | Vanguard Group Inc | 2023-12-31 | 179.5 K |
Corbus Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (10.0M) | 54.7M | (60.8M) | (8.0M) | (3.3M) | (3.1M) | |
| Free Cash Flow | (48.5M) | (100.2M) | (48.2M) | (37.6M) | (36.1M) | (37.9M) | |
| Other Non Cash Items | 45.8K | 291.4K | 950.6K | 1.6M | 1.0B | 1.1B | |
| Capital Expenditures | 707.4K | 2.3M | 2.7M | 484.5K | 54.2K | 13.4K | |
| Net Income | (71.5M) | (111.3M) | (45.6M) | (42.3M) | (44.6M) | (46.8M) | |
| End Period Cash Flow | 31.7M | 86.5M | 25.7M | 17.7M | 13.9M | 13.2M | |
| Change To Inventory | 5.4M | 9.6M | (1.1M) | (1.6M) | (1.9M) | (1.8M) | |
| Net Borrowings | (3.2M) | 18.7M | 57.8K | (533.6K) | (613.7K) | (583.0K) | |
| Depreciation | 1.2M | 1.7M | 1.6M | 1.5M | 641K | 834.2K | |
| Change To Netincome | 12.0M | 12.8M | 10.8M | 6.6M | 7.6M | 7.3M | |
| Investments | (2.7M) | (484.5K) | (73.4M) | 30.1M | 37.0M | 38.9M |
Corbus Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Corbus Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Corbus Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Corbus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 4.58 | |
β | Beta against NYSE Composite | 3.77 | |
σ | Overall volatility | 32.94 | |
Ir | Information ratio | 0.15 |
Corbus Pharmaceuticals Volatility Alert
Corbus Pharmaceuticals Holding is showing large volatility of returns over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Corbus Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Corbus Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Corbus Pharmaceuticals Fundamentals Vs Peers
Comparing Corbus Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Corbus Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Corbus Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Corbus Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Corbus Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Corbus Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Corbus Pharmaceuticals to competition |
| Fundamentals | Corbus Pharmaceuticals | Peer Average |
| Return On Equity | -3.42 | -0.31 |
| Return On Asset | -0.6 | -0.14 |
| Current Valuation | 395.57 M | 16.62 B |
| Shares Outstanding | 10.51 M | 571.82 M |
| Shares Owned By Insiders | 0.69 % | 10.09 % |
| Shares Owned By Institutions | 56.96 % | 39.21 % |
| Number Of Shares Shorted | 475.63 K | 4.71 M |
| Price To Earning | (8.87) X | 28.72 X |
| Price To Book | 1,491 X | 9.51 X |
| Price To Sales | 163.32 X | 11.42 X |
| Gross Profit | (16.14 M) | 27.38 B |
| EBITDA | (44.44 M) | 3.9 B |
| Net Income | (44.6 M) | 570.98 M |
| Cash And Equivalents | 66.23 M | 2.7 B |
| Cash Per Share | 0.53 X | 5.01 X |
| Total Debt | 20.88 M | 5.32 B |
| Debt To Equity | 0.61 % | 48.70 % |
| Current Ratio | 3.86 X | 2.16 X |
| Book Value Per Share | (1.56) X | 1.93 K |
| Cash Flow From Operations | (36.1 M) | 971.22 M |
| Short Ratio | 1.24 X | 4.00 X |
| Earnings Per Share | (10.31) X | 3.12 X |
| Target Price | 55.0 | |
| Number Of Employees | 19 | 18.84 K |
| Beta | 2.47 | -0.15 |
| Market Capitalization | 396.12 M | 19.03 B |
| Total Asset | 28.27 M | 29.47 B |
| Retained Earnings | (436.68 M) | 9.33 B |
| Working Capital | (8.35 M) | 1.48 B |
| Current Asset | 12.71 M | 9.34 B |
| Current Liabilities | 3.63 M | 7.9 B |
| Net Asset | 28.27 M |
Note: Disposition of 1787 shares by Sean Moran of Corbus Pharmaceuticals at 30.0 subject to Rule 16b-3 [view details]
Corbus Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Corbus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Corbus Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Corbus Pharmaceuticals Holding? Buying financial instruments such as Corbus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 26.6M | 25.1M | 20.9M | 11.1M | Total Assets | 107.7M | 66.3M | 28.3M | 50.5M |
Use Investing Ideas to Build Portfolios
In addition to having Corbus Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronics Thematic Idea Now
Electronics
Companies manufacturing electronic appliances and goods. The Electronics theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronics Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Corbus Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Corbus Stock analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.60) | Return On Equity (3.42) |
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.